(Corrects spelling of AstraZeneca in headline)
Jan 25 (Reuters) - AstraZeneca PLC:
* ASTRAZENECA PLC - CALQUENCE APPROVED IN JAPAN FOR CLL
* ASTRAZENECA - CALQUENCE APPROVED IN JAPAN FOR TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA
* ASTRAZENECA - 88% OF PATIENTS ON CALQUENCE REMAINED FREE OF DISEASE PROGRESSION AFTER 12 MONTHS VERSUS. 68% FOR COMPARATORS
* ASTRAZENECA - JAPANESE PHASE I/II TRIAL BASED ON ELEVATE TN PHASE III TRIAL IS CURRENTLY UNDERWAY FOR TREATMENT OF 1ST-LINE CLL Source text for Eikon: Further company coverage:
我们的标准: 汤森路透“信任原则”